Published on
11:25 GMT
Formycon First Enters FDA Review in $42B Keytruda Biosimilar Race
The global race to capture a share of the market for biosimilars of Keytruda, the world’s top-selling drug by revenue, has reached a key regulatory milestone in the United States. Germany’s Formycon has become the first company to publicly announce that …
Source:
Business Korea
-
Neutral
